Media coverage about TIGENIX/S (NASDAQ:TIG) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TIGENIX/S earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.2775291291916 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, ValuEngine raised TIGENIX/S from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $44.90.
TIG stock remained flat at $$41.98 during trading on Monday. The company has a quick ratio of 0.69, a current ratio of 0.71 and a debt-to-equity ratio of 0.24. The company has a market cap of $545.66 million, a P/E ratio of -2,099.00 and a beta of 4.52. TIGENIX/S has a 1-year low of $19.24 and a 1-year high of $48.00.
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Read More: Outstanding Shares
Receive News & Ratings for TIGENIX/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TIGENIX/S and related companies with MarketBeat.com's FREE daily email newsletter.